Clinical Trials
2 trialsNCT00667862 2021-06-21
Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
Novartis
Phase 2 Completed
NCT00663832 2020-12-19
A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
Novartis
Phase 1 Completed